• Tips gratefully accepted here. Thanks!:

  • Recent Comments

    bellecat on Last GoT post, I promise
    bellecat on Last GoT post, I promise
    Catscatscats on Last GoT post, I promise
    bellecat on Last GoT post, I promise
    William on Last GoT post, I promise
    William on Last GoT post, I promise
    Catscatscats on Last GoT post, I promise
    Catscatscats on Last GoT post, I promise
    Ivory Bill Woodpecke… on Last GoT post, I promise
    centaur on Last GoT post, I promise
    Ivory Bill Woodpecke… on Last GoT post, I promise
    Williiam on Last GoT post, I promise
    William on Last GoT post, I promise
    Catscatscats on Last GoT post, I promise
    Ivory Bill Woodpecke… on Last GoT post, I promise
  • Categories


  • Tags

    abortion Add new tag Afghanistan Al Franken Anglachel Atrios bankers Barack Obama Bernie Sanders big pharma Bill Clinton cocktails Conflucians Say Dailykos Democratic Party Democrats Digby DNC Donald Trump Donna Brazile Economy Elizabeth Warren feminism Florida Fox News General Glenn Beck Glenn Greenwald Goldman Sachs health care Health Care Reform Hillary Clinton Howard Dean John Edwards John McCain Jon Corzine Karl Rove Matt Taibbi Media medicare Michelle Obama Michigan misogyny Mitt Romney Morning Edition Morning News Links Nancy Pelosi New Jersey news NO WE WON'T Obama Obamacare OccupyWallStreet occupy wall street Open thread Paul Krugman Politics Presidential Election 2008 PUMA racism Republicans research Sarah Palin sexism Single Payer snark Social Security Supreme Court Terry Gross Texas Tim Geithner unemployment Wall Street WikiLeaks women
  • Archives

  • History

    May 2019
    S M T W T F S
    « Apr    
     1234
    567891011
    12131415161718
    19202122232425
    262728293031  
  • RSS Paul Krugman: Conscience of a Liberal

  • The Confluence

    The Confluence

  • RSS Suburban Guerrilla

    • An error has occurred; the feed is probably down. Try again later.
  • RSS Ian Welsh

    • The politics you’ve got
      MANDOS POST Take a look at Joe Biden—he appears to have, for now at least, considerable staying power in the Democratic primary opinion polls (although, of course, this may change as the actual primaries come through). If your model of political psychology can predict a strong core of popular support for Trump without also predicting […]
  • Top Posts

  • Advertisements

When I told you Research had left NJ, I wasn’t making it up

 

Hoffman-LaRoche Nutley, NJ- recently shuttered.

NPR ran a recent piece on the problem of ghost towns being left in the wake of the great pharma mergers and layoffs of the last 10 years.

The facility I worked at in Bridgewater, NJ closed in 2011.  I’m not sure they were able to find renters but the MBAs seemed to have a habit of overestimating what new tenants for labs space would be willing (or able) to pay.  The lab buildings I worked in were beautiful with lots of natural light but they were never full. The facility I worked at previously in Monmouth Junction, NJ was also abandoned for awhile but I had heard that there were some plans to lease it.  Or bulldoze it.  I can’t remember which.  I stand corrected.  Google maps says the site is “closed”.  That building was smaller and more contained.  It would have been perfect for a small biotech company on the rise.  It had a state of the art animal breeding facility and room for about 400 people. More than that makes it feel too cozy.

But as I wrote back in 2011, it is difficult to get funding for a startup.  The vulture capitalists like to see most of the work done before they commit their money.  Then there is the problem of finding money for equipment (this is cheaper due to the big pharmas auctioning off all their stuff), subscriptions to journals, buying expertise for robotic HTS assays, structural

The place where I spent the best years of my life

biology, specialized analytical chemistry and ADME analysis, and every other thing that a small biotech doesn’t have in its own arsenal.  A regular Joe researcher funding his own research will probably lose his house before the year is out.  So, he and his colleagues don’t have a whole lot of money to spend on lab space, which despite its abundance, is going to be expensive.

In the meantime, Big Pharma is counting on graduate students living on subsistence wages to pick up the slack on what are now reduced government grants.  It was hard enough to be a graduate student in Chemistry before the sequester.  Now, the money is much harder to come by.  For a person who may not get a decent paying job until he or she is almost 30, the prospects are bleak.

You can see Paul Krugman from here!

You can see Paul Krugman from here!

Funny how Paul Krugman doesn’t talk about this.  He’s living in the heart of what was Big Pharma territory and the desolation is hard to ignore.

Some of the lame excuses that Big Pharma gives for pulling out of NJ is that it’s too far from the City and the kids nowadays want to be right in the middle of some hot urban action, complete with expensive tiny apartments that they will have to share with roommates until they retire.  Also, Big Pharma has relocated to the coasts to be close to Harvard, MIT, Stanford and Scripps.  That’s so they can share ideas in the areas where genomics and molecular biology are king.  But this is utter bullshit.  For one thing, if you are working in Cambridge, MA or San Francisco, you are precluded from talking about your work with anyone.  There’s no sharing going on in the spirit of the Scientific Revolution of the 17th century.  It’s all proprietary and very hush, hush.  Your work won’t be published until the lawyers have taken out anything that’s remotely patentable.  It could be years before you can share your big breakthrough.

Plus, there is this new fangled device called the internet.  If I wanted to, I could use an online tool to order up a synthetic gene from California from the comfort of my backyard wisteria covered swing in Pittsburgh.  I can access thousands of journal articles, provided I had $33/electronic copy and could get over my impulse to strangle the ACS and Elsevier every time I had to do it.  I could attend meetings and conferences.  My work does not depend on my location.

And here’s one more reason why pulling out of NJ to go to Boston doesn’t make sense.  It’s fricking expensive.  If the MBAs were trying to save money, which is what they always claim is the reason for shuttering labs, why the hell would they relocate to some of the most expensive real estate in America??  Why not go back to the midwest where the mothballed labs are still cheap?  That’s where most of research was before the big mega mergers in the 90s brought everyone to the Northeast.  Cinncinnati, Kalamazoo, Ann Arbor all had thriving research communities before the business people decided to manage things.  Or even Pittsburgh.  This place is hopping lately, it’s urban, housing is cheap and there’s plenty of mass transit.

And this is where I think we come to the crux of the matter.  The relocation is about what the business people want.  They don’t want to be stuck in dowdy, suburban NJ with the high property taxes and they can’t think past the rust belt image of the midwest.  It’s not glamorous enough for the people who consider themselves the culture of smartness.  Smartness demands that it hang around other smart people.  Maybe if the business types rub shoulders with the supersmart MIT researchers, they won’t feel like they sold out their biology degrees to become finance wizards?  Projection of sorts?  I can only guess.

It’s also easier to jettison your workforce if you claim you HAVE to move to stay competitive.  Yep, just cut those hundreds of thousands of experienced STEM workers loose when they are in middle age and have family responsibilities.  Leave them stranded in NJ while their property values sink and they are stuck peddling themselves as consultants from one poverty stricken startup after another.

This is no way to treat the people who brought you Lipitor, Effexor and Allegra.  And, yet, this is the way it’s going.  Big Pharma sees its future as chronic illness specialists.  They will charge hundreds of thousands of dollars a year for a drug that some people can’t live without and will expect insurance companies to pay for them.  Think of it as sponge from some Nathan Brazil Well World novel. I know that a few of my friends are still making a living in companies that are focusing on orphan diseases and oncology but there’s something immoral about hooking up people to drugs you know they can’t live without with the goal of milking every dollar from them.  I realize that research is expensive but we didn’t use to be so mercenary about it.  Instead of solving the problem of out of control research costs, the new wizards of pharma finance have glommed onto cheap, dirty and unsustainable new ways to make money. Reduce your workforce to desperation, focus on the poor unfortunate chronically ill and ignore everyone else. This is the new business model.

And it is broken.

Advertisements

Harvard Faculty Have Had Enough

This post is all over the blogosphere today.  The Faculty Advisory Council at Harvard is saying enough is enough to the publishers of scientific journals.  The costs of these publications and the new subscription bundles are extortionary:

Perhaps this announcement is simply part of a negotiating strategy (one would expect Harvard librarians to be a clever bunch). But, be that as it may, what is particularly striking is the advice offered to staff regarding what they can do to help the situation, which chimes with what I and many others have been arguing as pathways to bolstering open access publishing (and was writing aboutonly yesterday). To pick out just two key phrases (with my emphases in bold):

“Consider submitting articles to open-access journals, or to ones that have reasonable, sustainable subscription costs; move prestige to open access.

If on the editorial board of a journal involved, determine if it can be published as open access material, or independently from publishers that practice pricing described above.If not, consider resigning.”

This sends an important message (one is tempted to the hyperbole that it may even be a ‘shot heard round the world’). If one of the most prestigious and richest institutions in the world cannot afford its journal subscriptions, then there is a serious problem in academic publishing.

 Atrios thinks that Harvard can handle the costs.  Maybe, but the rest of us can’t and, anyway, that’s not the point. The point is that as long as big institutional licensees keep shelling out millions of dollars in subscription fees, the rest of us, small companies and independent scientists, are going to be forced to follow the publishers’ fee structures.  For those of you who have never had to download a paper, try coughing up $35/paper.  If you’re starting a new project in a biotech area requiring some background research, literature costs can easily get out of control and be a significant drag on the limited funds available.

There’s really no excuse for this business model except that publishers like it this way and now that there are a lot of companies downsizing, they just jack up the costs on everyone else to maintain their profit margins.  They refuse to evolve so Harvard may be striking the first blow to make them do it.  I want to see an iTunes type model where papers cost no more than a couple of bucks  for a digital copy that I can download to my Notability app.  Journals are not printed anymore, the content is provided to the publishers for nothing and in many cases, already pre-formatted.  So, this crap has got to stop.  No more stranglehold on scientific information.

Go Harvard.